Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association between attention deficit hyperactivity disorder and keratoconus.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie·2026

Same author

Adenocarcinoma Arising from Unilateral Retinal Pigment Epithelium Dysgenesis.

Journal of vitreoretinal diseases·2026

Same author

Post-Marketing Ocular Adverse Events Associated with Tamoxifen and Raloxifene: A Population-Based Pharmacovigilance Study.

Retina (Philadelphia, Pa.)·2026

Same author

Drug-associated lacrimal drainage obstruction: a population-based pharmacovigilance study.

Orbit (Amsterdam, Netherlands)·2026

Same author

Optical Coherence Tomography Biomarkers as Potential Predictors for Visual Function and Response to Intravitreal Therapy in Diabetic Macular Edema.

Journal of vitreoretinal diseases·2026

Same author

Bilateral Papillitis and Unilateral Central Serous Retinopathy Associated with Dabrafenib and Trametinib Use in Metastatic Cutaneous Melanoma.

Neuro-ophthalmology (Aeolus Press)·2026

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Medicare Trends in Intravitreal Anti-VEGF Use: A Population-Based Study (2014-2023).

Salem Abu Al-Burak¹, Justin Shad², Andrew Mihalache³

¹Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.

Ophthalmology. Retina

|March 11, 2026

Summary

Intravitreal anti-VEGF injections for Medicare beneficiaries increased from 2014-2023, driven by aflibercept and faricimab. Reimbursement declined for some agents, and geographic disparities in use persisted.

Keywords:

Claims data Health care utilization Intravitreal anti-VEGF Medicare Reimbursement

More Related Videos

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Related Experiment Videos

Last Updated: Mar 13, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Area of Science:

Ophthalmology
Health Economics
Health Services Research

Background:

Intravitreal anti-VEGF agents are crucial for treating retinal diseases.
Understanding utilization trends and reimbursement is vital for healthcare policy.

Purpose of the Study:

To analyze national trends in intravitreal anti-VEGF use among Medicare beneficiaries.
To examine reimbursement patterns and geographic variations from 2014 to 2023.

Main Methods:

Retrospective cross-sectional study using Medicare Part B data (2014-2023).
Included beneficiaries receiving anti-VEGF injections (aflibercept, ranibizumab, bevacizumab, brolucizumab, faricimab).
Analyzed injection counts, beneficiary numbers, reimbursement, and state-level utilization rates.

Main Results:

Total injections increased significantly, led by aflibercept and rapid faricimab adoption.
Reimbursement per injection declined for ranibizumab and aflibercept.
Significant geographic variation in utilization rates was observed across states.

Conclusions:

Intravitreal anti-VEGF use grew substantially, with shifts in agent preference.
Declining reimbursement for some agents and persistent geographic disparities highlight market dynamics.
Ongoing monitoring is essential with new agents and delivery systems emerging.